2-脒基吡啶盐酸盐 | 51285-26-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-脒基吡啶盐酸盐
• 中文别名: 2-吡啶脒盐酸盐；2-甲脒基吡啶盐酸盐
• 英文名称: pyridine-2-carboxamidine hydrochloride
• 英文别名: picolinimidamide hydrochloride；2-amidinopyridine hydrochloride；pyridine-2-carboximidamide hydrochloride；2-amidinopyridinium chloride；2-amidinopyridinium hydrochloride；2-pyridine carboximidamide hydrochloride；2-pyridinecarboxamidine hydrochloride；picolinamidine hydrochloride；pyridine-2-carboximidamide;hydrochloride
• CAS: 51285-26-8
• 化学式: C₆H₇N₃*ClH
• mdl: MFCD00052271
• 分子量: 157.603
• InChiKey: GMHCEDDZKAYPLB-UHFFFAOYSA-N

物化性质

• 熔点：
  150-152°C
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，且未有已知危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  0.06
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将贮藏器保持密封，并存放在阴凉、干燥处。确保工作环境有良好的通风或排气设施。

SDS

Name:	Pyridine-2-carboximidamide hydrochloride 97% Material Safety Data Sheet
Synonym:	2-Amidinopyridine hydrochloride2-Amidinopyridinium hydrochlorid
CAS:	51285-26-8

Section 1 - Chemical Product MSDS Name:Pyridine-2-carboximidamide hydrochloride 97% Material Safety Data Sheet
Synonym:2-Amidinopyridine hydrochloride2-Amidinopyridinium hydrochlorid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
51285-26-8	Pyridine-2-carboximidamide hydrochlori	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.Hygroscopic (absorbs moisture from the air).
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 51285-26-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white crystalline solid
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 143 - 145 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H8ClN3
Molecular Weight: 158

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Oxidizing agents, bases, acid chlorides.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 51285-26-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Pyridine-2-carboximidamide hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 51285-26-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 51285-26-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 51285-26-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-脒基吡啶盐酸盐 在 sodium ethanolate 、 三氯氧磷 作用下， 以 乙醇 、 1,2-二氯乙烷 为溶剂， 反应 18.0h， 生成 4-氯-2-吡啶-2-基-嘧啶
  参考文献：
  名称：

  Structure–activity relationship of thiopyrimidines as mGluR5 antagonists

  摘要：

  Structure-activity relationship investigations of the thiopyrimidine (1), an HTS hit with micromolar activity as a metabotropic glutamate receptor 5 (mGluR5) antagonist, led to compounds with sub-micromolar activity. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.100
• 作为产物：
  描述：

  2-氰基吡啶 在 sodium 、 氯化铵 作用下， 以 甲醇 为溶剂， 反应 20.0h， 以88%的产率得到2-脒基吡啶盐酸盐
  参考文献：
  名称：

  一系列带有双齿嘧啶配体的 Cp*Ir(III) 配合物环金属化的气相研究

  摘要：

  合成和气相实验的协同方法表征了一系列阳离子 η 5的相对环金属化势垒-Cp* 铱（III）化合物。所研究化合物的共同特征是双齿 N,N'-供体配体，其具有在 2-位上用 5-丁基嘧啶-2-基环官能化的吡啶位点。此外，吡啶环被给电子或吸电子基团官能化。通过NMR和IR光谱以及元素分析表征化合物。为了测量环金属化的相对势垒，进行了碰撞诱导解离（CID）实验，这揭示了相对势垒与吡啶环上取代基的性质和位置的明显依赖性。

  DOI：

  10.1016/j.jorganchem.2021.122063
• 作为试剂：
  描述：

  3-溴-2-氯苯乙腈 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 、 氯化镍二甲氧基乙烷 、 硫酸 、 2-脒基吡啶盐酸盐 、 sodium methylate 、 potassium acetate 、 caesium carbonate 、 溶剂黄146 、 锌 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N,N-二甲基乙酰胺 、 水 为溶剂， 反应 21.0h， 生成 3-(2-chloro-4'-((4-(oxetan-3-yl)pyrimidin-2-yl)methyl)-[1,1'-biphenyl]-3-yl)piperidine-2,6-dione
  参考文献：
  名称：

  TARGETED DEGRADATION OF VAV1

  摘要：

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having an inflammatory or autoimmune disorder.

  公开号：

  WO2024151547A1

文献信息

• [EN] IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS IMIDAZOLE UTILES COMME INHIBITEURS DE LA FAAH
  申请人：MERCK & CO INC

  公开号：WO2009152025A1

  公开（公告）日：2009-12-17

  The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

  本发明涉及某些咪唑衍生物，其可用作脂肪酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病性神经病、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• [EN] NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SERVIER LAB

  公开号：WO2015097123A1

  公开（公告）日：2015-07-02

  Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.

  式（I）的化合物：其中R1、R2、R3、R4、R5、R6、R7、R12、X、A和n的定义如描述中所述。
• [EN] TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS<br/>[FR] TÉTRAHYDROPYRIDOPYRIMIDINES ET TÉTRAHYDROPYRIDOPYRIDINES COMME INHIBITEURS D'AG HBS (ANTIGÈNE DE SURFACE DU VIRUS DE L'HÉPATITE B) ET PRODUCTION D'ADN DE VHB POUR LE TRAITEMENT D'INFECTIONS PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016177655A1

  公开（公告）日：2016-11-10

  The present invention provides tetrahydropyridopyrimidines and tetrahydropyridopyridines having the general formula (I) wherein R1, R2, U, W, X, Y and Z are as described herein, as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment and prophylaxis of hepatitis B virus infections.

  本发明提供了具有一般式(I)的四氢吡啶嘧啶和四氢吡啶吡啶，其中R1、R2、U、W、X、Y和Z如本文所述，作为乙型肝炎病毒表面抗原（HBsAg）和HBV DNA的抑制剂，用于治疗和预防乙型肝炎病毒感染。
• HFO‐1234yf as a CF ₃ ‐Building Block: Synthesis and Chemistry of CF ₃ ‐Ynones
  作者：Ben J. Murray、Thomas G. F. Marsh、Dmitri S. Yufit、Mark A. Fox、Antal Harsanyi、Lee T. Boulton、Graham Sandford

  DOI：10.1002/ejoc.202001071

  日期：2020.10.22

  diisopropylamide (LDA) leads to formation of lithium 3,3,3‐trifluoropropynide, addition of which to a range of aldehydes formed CF3‐alkynyl alcohol derivatives on multigram scale, which were oxidised using Dess‐Martin periodinane (DMP) to give substituted CF3‐ynones with minimal purification required. Michael‐type additions of alcohol and amine nucleophiles to CF3‐ynones are rapid and selective, affording

  低成本、易得的第 4 代制冷剂气体 2,3,3,3-四氟丙烯 (HFO-1234yf) 与二异丙基氨基锂 (LDA) 的反应导致形成 3,3,3-三氟丙炔化锂，添加到一定范围内醛形成数克规模的 CF3-炔醇衍生物，使用戴斯-马丁高碘烷 (DMP) 将其氧化以得到取代的 CF3-炔酮，所需的纯化最少。醇和胺亲核试剂向 CF3-炔酮的迈克尔型加成是快速和选择性的，以优异的收率提供一系列 CF3-烯酮醚和烯胺酮，对 Z-异构体具有高立体选择性。通过与双功能亲核试剂的类似反应，可以获得广泛的 CF3 取代的药学相关杂环结构，
• Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：——

  公开号：US20030045546A1

  公开（公告）日：2003-03-06

  The present invention is directed to substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: 1 wherein Ar 1 , Ar 3 , A, B and D are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及取代的3-芳基-5-芳基-[1,2,4]-噁二唑及其类似物，由以下式I表示： 1 其中Ar1，Ar3，A，B和D在此处定义。本发明还涉及发现具有式I的化合物是caspase的激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导在各种临床病况中发生未受控制的异常细胞生长和扩散的细胞死亡。